Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, two arm, open-label, randomized, study to investigate the effect of food on the bioavailability of a single 800 mg imatinib dose in modified release formulations (MR3 and MR4) and compare the bioavailability between MR3, MR4 and imatinib 400 mg twice daily immediate release tablet (IR) in healthy subjects

Next Previous
X
Search
Trial Profile

A phase I, two arm, open-label, randomized, study to investigate the effect of food on the bioavailability of a single 800 mg imatinib dose in modified release formulations (MR3 and MR4) and compare the bioavailability between MR3, MR4 and imatinib 400 mg twice daily immediate release tablet (IR) in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Malignant melanoma; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Novartis

    • Most Recent Events

    • 28 Jan 2008 Status change from in progress to completed.
    • 08 Feb 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top